Article Sidebar

Submitted
Jun 14, 2023
Published
Jun 24, 2024
Download
Pdf
Statistic
Read Counter : 325 Download : 312

Downloads

Download data is not yet available.

Main Article Content

Abstract

Patients with chronic kidney disease experience decreased kidney function (as an organ of elimination) and receive various drugs, so they are susceptible to Drug Related Problems (DRP). This study aimed to identify the type of potential DRP and analyzed the influence of gender, age, number of drugs, co-morbidities and length of stay on the incidence of DRP in hospitalized chronic kidney disease patients. This study was a cross-sectional study with retrospective data collection. The subjects of the study were chronic kidney disease patients who underwent hospitalization at a hospital in Surakarta at 2016-2021. The incidence of DRP was analyzed descriptively using the PCNE V9.1 algorithm, while the associations between risk factors and the incidence of DRP was analyzed statistically using the Fisher’s Exact Test. Data were obtained from 54 patients whose progress was followed up through medical record. The results showed that 36 patients (66.67%) had DRP while 18 patients (33.33%) did not. In the Problem category there were 22 events while in the Cause category there were 34 events. The results of statistical analysis using the Fisher's Exact Test showed that there were no significant associations between the risk factors (gender, age, number of drugs, number of co-morbidities, length of stay) and the incidence of DRP in hospitalized chronic kidney disease patients.

Keywords

Drug related problems Chronic kidney disease Hospital patients

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

References

  1. Al Hamid, A., Ghaleb, M., Aljadhey, H., & Aslanpour, Z. (2014). A systematic review of hospitalization resulting from medicine‐related problems in adult patients. British Journal of Clinical Pharmacology, 78(2), 202–217. https://doi.org/10.1111/bcp.12293
  2. Alomar, M. J. (2014). Factors affecting the development of adverse drug reactions (Review article). Saudi Pharmaceutical Journal, 22(2), 83–94. https://doi.org/10.1016/j.jsps.2013.02.003
  3. Artom, M., Moss-Morris, R., Caskey, F., & Chilcot, J. (2014). Fatigue in advanced kidney disease. Kidney International, 86(3), 497–505. https://doi.org/10.1038/ki.2014.86
  4. Barrett, P. M., McCarthy, F. P., Evans, M., Kublickas, M., Perry, I. J., Stenvinkel, P., Khashan, A. S., & Kublickiene, K. (2020). Hypertensive disorders of pregnancy and the risk of chronic kidney disease: A Swedish registry-based cohort study. PLOS Medicine, 17(8), e1003255. https://doi.org/10.1371/journal.pmed.1003255
  5. Bird, S. T., Delaney, J. A. C., Brophy, J. M., Etminan, M., Skeldon, S. C., & Hartzema, A. G. (2013). Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology. BMJ, 347(nov05 3), f6320–f6320. https://doi.org/10.1136/bmj.f6320
  6. BPOM RI. (2020). Informasi Obat Nasional Indonesia (IONI). CV Sagung Seto.
  7. Camilleri, M., Parkman, H. P., Shafi, M. A., Abell, T. L., & Gerson, L. (2013). Clinical Guideline: Management of Gastroparesis. American Journal of Gastroenterology, 108(1), 18–37. https://doi.org/10.1038/ajg.2012.373
  8. Carrero, J. J., Hecking, M., Chesnaye, N. C., & Jager, K. J. (2018). Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. Nature Reviews Nephrology, 14(3), 151–164. https://doi.org/10.1038/nrneph.2017.181
  9. Dagli, R. J., & Sharma, A. (2014). Polypharmacy: a global risk factor for elderly people. Journal of International Oral Health : JIOH, 6(6), i–ii. http://www.ncbi.nlm.nih.gov/pubmed/25628499
  10. Daugirdas, J. T., Depner, T. A., Inrig, J., Mehrotra, R., Rocco, M. V., Suri, R. S., Weiner, D. E., Greer, N., Ishani, A., MacDonald, R., Olson, C., Rutks, I., Slinin, Y., Wilt, T. J., Rocco, M., Kramer, H., Choi, M. J., Samaniego-Picota, M., Scheel, P. J., Brereton, L. (2015). KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update. American Journal of Kidney Diseases, 66(5), 884–930. https://doi.org/10.1053/j.ajkd.2015.07.015
  11. Fatimah, S. H., Cahyawati, W. A. S. N., & Panghiyangani, R. (2023). Hubungan Nilai Mini Nutritional Assessment (MNA) dengan Lama Rawat Inap. Homeostasis, 5(3), 616. https://doi.org/10.20527/ht.v5i3.7735
  12. Garedow, A. W., Mulisa Bobasa, E., Desalegn Wolide, A., Kerga Dibaba, F., Gashe Fufa, F., Idilu Tufa, B., Debalke, S., & Kumela Goro, K. (2019). Drug-Related Problems and Associated Factors among Patients Admitted with Chronic Kidney Disease at Jimma University Medical Center, Jimma Zone, Jimma, Southwest Ethiopia: A Hospital-Based Prospective Observational Study. International Journal of Nephrology, 2019, 1–9. https://doi.org/10.1155/2019/1504371
  13. Garin, N., Sole, N., Lucas, B., Matas, L., Moras, D., Rodrigo-Troyano, A., Gras-Martin, L., & Fonts, N. (2021). Drug related problems in clinical practice: a cross-sectional study on their prevalence, risk factors and associated pharmaceutical interventions. Scientific Reports, 11(1), 883. https://doi.org/10.1038/s41598-020-80560-2
  14. Harris, R. C., & Zhang, M.-Z. (2020). The role of gender disparities in kidney injury. Annals of Translational Medicine, 8(7), 514–514. https://doi.org/10.21037/atm.2020.01.23
  15. James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., Smith, S. C., Svetkey, L. P., Taler, S. J., Townsend, R. R., Wright, J. T., Narva, A. S., & Ortiz, E. (2014). 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. JAMA, 311(5), 507. https://doi.org/10.1001/jama.2013.284427
  16. Jankowski, J., Floege, J., Fliser, D., Böhm, M., & Marx, N. (2021). Cardiovascular Disease in Chronic Kidney Disease. Circulation, 143(11), 1157–1172. https://doi.org/10.1161/CIRCULATIONAHA.120.050686
  17. Katzung, B. G. (2018). Basic & clinical pharmacology (Michael Weitz & Peter Boyle (14th ed.). McGraw-Hill Education.
  18. Kaufmann, C. P., Stämpfli, D., Hersberger, K. E., & Lampert, M. L. (2015). Determination of risk factors for drug-related problems: a multidisciplinary triangulation process. BMJ Open, 5(3), e006376. https://doi.org/10.1136/bmjopen-2014-006376
  19. KDIGO. (2013). Chapter 1: Definition and classification of CKD. Kidney International Supplements, 3(1), 19–62. https://doi.org/10.1038/kisup.2012.64
  20. Klammt, S., Wojak, H.-J., Mitzner, A., Koball, S., Rychly, J., Reisinger, E. C., & Mitzner, S. (2012). Albumin-binding capacity (ABiC) is reduced in patients with chronic kidney disease along with an accumulation of protein-bound uraemic toxins. Nephrology Dialysis Transplantation, 27(6), 2377–2383. https://doi.org/10.1093/ndt/gfr616
  21. Lea-Henry, T. N., Carland, J. E., Stocker, S. L., Sevastos, J., & Roberts, D. M. (2018). Clinical Pharmacokinetics in Kidney Disease. Clinical Journal of the American Society of Nephrology, 13(7), 1085–1095. https://doi.org/10.2215/CJN.00340118
  22. Mason, N. A., & Bakus, J. L. (2010). Strategies for Reducing Polypharmacy and Other Medication‐Related Problems in Chronic Kidney Disease. Seminars in Dialysis, 23(1), 55–61. https://doi.org/10.1111/j.1525-139X.2009.00629.x
  23. Mohammed, I., Syed, W., & Kowey, P. R. (2013). Oral Anticoagulants to Reduce the Risk of Stroke in Atrial Fibrillation: How Should a Clinician Choose? Clinical Cardiology, 36(11), 663–670. https://doi.org/10.1002/clc.22173
  24. Movva, R., Jampani, A., Nathani, J., Pinnamaneni, S., & Challa, S. (2015). A prospective study of incidence of medication-related problems in general medicine ward of a tertiary care hospital. Journal of Advanced Pharmaceutical Technology & Research, 6(4), 190. https://doi.org/10.4103/2231-4040.166502
  25. Neiman, A. B., Ruppar, T., Ho, M., Garber, L., Weidle, P. J., Hong, Y., George, M. G., & Thorpe, P. G. (2017). CDC Grand Rounds: Improving Medication Adherence for Chronic Disease Management — Innovations and Opportunities. MMWR. Morbidity and Mortality Weekly Report, 66(45), 1248–1251. https://doi.org/10.15585/mmwr.mm6645a2
  26. Oliveros, E., Patel, H., Kyung, S., Fugar, S., Goldberg, A., Madan, N., & Williams, K. A. (2020). Hypertension in older adults: Assessment, management, and challenges. Clinical Cardiology, 43(2), 99–107. https://doi.org/10.1002/clc.23303
  27. PCNE. (2020). PCNE Classification for Drug-Related Problems V9.1. PCNE Association, 1(2), 22–28. http://www.pcne.org/upload/files/15_PCNE_classification_V4-00.pdf
  28. Saldanha, V., Araújo, I. B. de, Lima, S. I. V. C., Martins, R. R., & Oliveira, A. G. (2020). Risk factors for drug-related problems in a general hospital: A large prospective cohort. PLOS ONE, 15(5), e0230215. https://doi.org/10.1371/journal.pone.0230215
  29. Sell, R., & Schaefer, M. (2020). Prevalence and risk factors of drug-related problems identified in pharmacy-based medication reviews. International Journal of Clinical Pharmacy, 42(2), 588–597. https://doi.org/10.1007/s11096-020-00976-8
  30. Shargel, L., & Yu, A. B. (2016). Applied Biopharmaceutics & Pharmacokinetics (7th ed.). MacGraw-Hill Education.
  31. Suwandi, J. F., & Pahlavi, I. R. (2016). Pemberian Terapi Ceftriakson terhadap Kadar Kalsium Urin. Jurnal Majority, 5(3), 111–117.
  32. Tonelli, M., & Riella, M. (2014). Chronic kidney disease and the aging population. Indian Journal of Nephrology, 24(2), 71. https://doi.org/10.4103/0971-4065.127881
  33. USRDS. (2020). USRDS Annual Data Report: Epidemiology of kidney disease in the United States.